ABSTRACT
Zika virus (ZIKV) infections can cause microcephaly and neurological disorders. However, the early infection events of ZIKV in neural cells remain to be characterized. Here, by using a combination of pharmacological and molecular approaches and the human glioblastoma cell T98G as a model, we first observed that ZIKV infection was inhibited by chloroquine and NH4Cl, indicating a requirement of low intracellular pH. We further showed that dynamin is required as the ZIKV entry was affected by the specific inhibitor dynasore, small interfering RNA (siRNA) knockdown of dynamin, or by expressing the dominant-negative K44A mutant. Moreover, the ZIKV entry was significantly inhibited by chlorpromazine, pitstop2, or siRNA knockdown of clathrin heavy chain, indicating an involvement of clathrin-mediated endocytosis. In addition, genistein treatment, siRNA knockdown of caveolin-1, or overexpression of a dominant-negative caveolin mutant impacted the ZIKV entry, with ZIKV particles being observed to colocalize with caveolin-1, implying that caveola endocytosis can also be involved. Furthermore, we found that the endocytosis of ZIKV is dependent on membrane cholesterol, microtubules, and actin cytoskeleton. Importantly, ZIKV infection was inhibited by silencing of Rab5 and Rab7, while confocal microscopy showed that ZIKV particles localized in Rab5- and Rab7-postive endosomes. These results indicated that, after internalization, ZIKV likely moves to Rab5-positive early endosome and Rab7-positive late endosomes before delivering its RNA into the cytoplasm. Taken together, our study, for the first time, described the early infection events of ZIKV in human glioblastoma cell T98G.
ABSTRACT
CCR5 serves as an essential coreceptor for human immunodeficiency virus type 1 (HIV-1) entry, and individuals with a CCR5(Δ32) variant appear to be healthy, making CCR5 an attractive target for control of HIV-1 infection. The CRISPR/Cas9, which functions as a naturally existing adaptive immune system in prokaryotes, has been recently harnessed as a novel nuclease system for genome editing in mammalian cells. Although CRISPR/Cas9 can be readily delivered into cell lines, due to the large size of the Cas9 protein, efficient delivery of CCR5-targeting CRISPR/Cas9 components into primary cells, including CD4(+) T-cells, the primary target for HIV-1 infection in vivo, remains a challenge. In the current study, following design of a panel of top-ranked single-guided RNAs (sgRNAs) targeting the ORF of CCR5, we demonstrate that CRISPR/Cas9 can efficiently mediate the editing of the CCR5 locus in cell lines, resulting in the knockout of CCR5 expression on the cell surface. Next-generation sequencing revealed that various mutations were introduced around the predicted cleavage site of CCR5. For each of the three most effective sgRNAs that we analysed, no significant off-target effects were detected at the 15 top-scoring potential sites. More importantly, by constructing chimeric Ad5F35 adenoviruses carrying CRISPR/Cas9 components, we efficiently transduced primary CD4(+) T-lymphocytes and disrupted CCR5 expression, and the positively transduced cells were conferred with HIV-1 resistance. To our knowledge, this is the first study establishing HIV-1 resistance in primary CD4(+) T-cells utilizing adenovirus-delivered CRISPR/Cas9.
Subject(s)
Adenoviridae/genetics , CD4-Positive T-Lymphocytes/virology , CRISPR-Cas Systems , Genetic Vectors/genetics , HIV Infections/genetics , HIV-1/physiology , Receptors, CCR5/genetics , Adenoviridae/metabolism , Animals , CD4-Positive T-Lymphocytes/immunology , Cell Line , Genetic Vectors/metabolism , HIV Infections/metabolism , HIV Infections/virology , HIV-1/genetics , High-Throughput Nucleotide Sequencing , Humans , Receptors, CCR5/metabolismSubject(s)
Hearing Loss/epidemiology , Adult , Aged , Child , Delivery of Health Care , Global Health , Hearing Loss/therapy , Humans , Middle AgedABSTRACT
Tetherin has been defined as a restriction factor of HIV-1 and several other enveloped viruses. However, the significance of tetherin in viral infection remains to be further addressed. Here, we investigated whether tetherin plays a role in HSV-2 infection. Our study revealed that overexpression of tetherin restricted the release of HSV-2 into the extracellular medium, while knockdown of tetherin by siRNA enhanced its release. We further demonstrated that HSV-2 infection and viral glycoproteins gB, gD, gH and gL but not gM significantly downregulated the endogenous expression of tetherin. Additional study indicated that tetherin likely physically interacted with gB, gD, gH and gL. This is the first time that tetherin has been shown to be counteracted by multiple viral components of a virus. Our findings inform the complexity of HSV-2-host interactions, providing basis for understanding the role of tetherin as a viral restriction factor and the mechanisms underlying viral countermeasures.
Subject(s)
Antigens, CD/metabolism , Glycoproteins/metabolism , Herpesvirus 2, Human/physiology , Animals , Antigens, CD/genetics , Cell Line , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Gene Knockdown Techniques , Glycoproteins/genetics , Humans , Polymerase Chain Reaction/methods , RNA Interference , Virus Internalization , Virus ReleaseABSTRACT
OBJECTIVE: To analyse the structural and kinetic response of small intestinal crypt epithelial cells including stem cells to highly active antiretroviral therapy (HAART). DESIGN: Crypt size and proliferative activity of transit and stem cells in jejunal mucosa were quantified using morphometric techniques. METHODS: Crypt length was measured by counting the number of enterocytes along one side of a number of crypts in each biopsy specimen and the mean crypt length was calculated. Proliferating crypt cells were identified with MIB-1 monoclonal antibody, and the percentage of crypt cells in proliferation was calculated at each cell position along the length of the crypt (proliferation index). Data were obtained from 9 HIV-positive test patients co-infected with microsporidia, 34 HIV-positive patients receiving HAART and 13 control cases. RESULTS: Crypt length was significantly greater in test patients than in controls, but crypt length in patients receiving HAART was normal. The proliferation index was greater in test subjects than in controls in stem and transit cell compartments, and was decreased in patients treated with HAART only in the stem cell region of the crypt. CONCLUSIONS: Villous atrophy in HIV enteropathy is attributed to crypt hypertrophy and encroachment of crypt cells onto villi. HAART restores normal crypt structure by inhibition of HIV-driven stem cell hyperproliferation at the crypt bases.
Subject(s)
Antiretroviral Therapy, Highly Active , Cell Proliferation/drug effects , HIV Enteropathy/pathology , Intestinal Mucosa/pathology , Stem Cells/drug effects , HIV Enteropathy/drug therapy , Humans , Hypertrophy/pathology , Intestinal Mucosa/drug effects , Jejunum/drug effects , Jejunum/pathology , Mitotic Index , Stem Cells/pathologyABSTRACT
Induction of broad and potent neutralizing Abs at the mucosal portals of entry remains a primary goal for most vaccines against mucosally acquired viral infections. Selection of appropriate adjuvants capable of promoting both systemic and mucosal responses will be crucial for the development of effective immunization strategies. In this study, we investigated whether plasmid codelivery of cytokines APRIL, CCL19, or CCL28 can enhance Ag-induced immune responses to HIV-1 gp140. Our results demonstrated that pCCL19 and pCCL28, but not pAPRIL, significantly enhanced Ag-specific systemic and mucosal Ab responses. gp140-specific Abs in serum enhanced by pCCL19 or pCCL28 were broadly distributed across all four IgG subclasses, of which IgG1 was predominant. The enhanced systemic and mucosal Abs showed increased neutralizing activity against both homologous and heterologous HIV-1, and potency correlated with gp140-specific serum IgG and vaginal IgA levels. Measurement of gp140-specific cytokines produced by splenocytes demonstrated that pCCL19 and pCCL28 augmented balanced Th1/Th2 responses. pCCL19 and pCCL28 also increased IgA(+) cells in colorectal mucosal tissue. pCCL19 codelivery resulted in an increase of CCR7(+) CD11c(+) cells in mesenteric lymph nodes and both CCR7(+) CD11c(+) cells and CCR7(+) CD3e(+) cells in spleen, whereas pCCL28 codelivery resulted in an augment of CCR10(+) CD19(+) cells in both spleen and mesenteric lymph nodes. Together, our data indicate that pCCL19 and pCCL28 can enhance HIV-1 envelope-specific systemic and mucosal Ab responses, as well as T cell responses. Such enhancements appear to be associated with mobilization of responsive immunocytes into secondary lymphoid organs and mucosal tissues through interactions with corresponding receptors.
Subject(s)
B-Lymphocyte Subsets/immunology , Chemokine CCL19/physiology , Chemokines, CC/physiology , HIV Antibodies/biosynthesis , Lymphoid Tissue/immunology , T-Lymphocyte Subsets/immunology , env Gene Products, Human Immunodeficiency Virus/immunology , AIDS Vaccines/immunology , Animals , Chemokine CCL19/genetics , Chemokines, CC/genetics , Chemotaxis , Female , Genetic Vectors/administration & dosage , HEK293 Cells , HIV Antibodies/immunology , HeLa Cells , Humans , Immunoglobulin Isotypes/biosynthesis , Immunoglobulin Isotypes/immunology , Immunophenotyping , Lymph Nodes/immunology , Mice , Mice, Inbred BALB C , Mucous Membrane/immunology , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/pharmacology , Specific Pathogen-Free Organisms , Tumor Necrosis Factor Ligand Superfamily Member 13/genetics , Tumor Necrosis Factor Ligand Superfamily Member 13/physiology , Vaccination , Vaccines, DNA/immunology , Vagina/immunologyABSTRACT
Early stages of mucosal infection are potential targets for HIV-1 prevention. CD4 is the primary receptor in HIV-1 infection whereas DC-SIGN likely plays an important role in HIV-1 dissemination, particularly during sexual transmission. To test the hypothesis that an inhibitor simultaneously targeting both CD4 and DC-SIGN binding sites on gp120 may provide a potent anti-HIV strategy, we designed constructs by fusing the extracellular CD4 and DC-SIGN domains together with varied arrangements of the lengths of CD4, DC-SIGN and the linker. We expressed, purified and characterized a series of soluble CD4-linker-DC-SIGN (CLD) fusion proteins. Several CLDs, composed of a longer linker and an extra neck domain of DC-SIGN, had enhanced affinity for gp120 as evidenced by molecular-interaction analysis. Furthermore, such CLDs exhibited significantly enhanced neutralization activity against both laboratory-adapted and primary HIV-1 isolates. Moreover, CLDs efficiently inhibited HIV-1 infection in trans via a DC-SIGN-expressing cell line and primary human dendritic cells. This was further strengthened by the results from the human cervical explant model, showing that CLDs potently prevented both localized and disseminated infections. This is the first time that soluble DC-SIGN-based bifunctional proteins have demonstrated anti-HIV potency. Our study provides proof of the concept that targeting both CD4 and DC-SIGN binding sites on gp120 represents a novel antiviral strategy. Given that DC-SIGN binding to gp120 increases exposure of the CD4 binding site and that the soluble forms of CD4 and DC-SIGN occur in vivo, further improvement of CLDs may render them potentially useful in prophylaxis or therapeutics.
Subject(s)
CD4 Antigens/genetics , Cell Adhesion Molecules/genetics , HIV Envelope Protein gp120/antagonists & inhibitors , HIV Infections/prevention & control , HIV-1/drug effects , Lectins, C-Type/genetics , Receptors, Cell Surface/genetics , Receptors, Virus/antagonists & inhibitors , Recombinant Fusion Proteins/genetics , Binding Sites , CD4 Antigens/metabolism , Cell Adhesion Molecules/metabolism , Cell Line , Dendritic Cells/cytology , Dendritic Cells/metabolism , Dendritic Cells/virology , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/metabolism , HIV Infections/transmission , HIV Infections/virology , HIV-1/growth & development , HIV-1/metabolism , Humans , Kinetics , Lectins, C-Type/metabolism , Plasmids , Primary Cell Culture , Receptors, Cell Surface/metabolism , Receptors, Virus/genetics , Receptors, Virus/metabolism , Recombinant Fusion Proteins/metabolism , Recombinant Fusion Proteins/pharmacology , Solubility , TransfectionABSTRACT
Recruitment of CD4(+) T cells to infection areas after HSV-2 infection may be one of the mechanisms that account for increased HIV-1 sexual transmission. Lymphocytes recruited by chemokine CXCL9 are known to be important in control of HSV-2 infection in mice, although the underlying mechanism remains to be addressed. Based on our observation that CXCL9 expression is augmented in the cervical mucus of HSV-2-positive women, in this study we demonstrate that HSV-2 infection directly induces CXCL9 expression in primary cervical epithelial cells and cell lines, the principal targets of HSV-2, at both mRNA and protein levels. Further studies reveal that the induction of CXCL9 expression by HSV-2 is dependent upon a binding site for C/EBP-ß within CXCL9 promoter sequence. Furthermore, CXCL9 expression is promoted at the transcriptional level through phosphorylating C/EBP-ß via p38 MAPK pathway, leading to binding of C/EBP-ß to the CXCL9 promoter. Chemotaxis assays indicate that upregulation of CXCL9 expression at the protein level by HSV-2 infection enhances the migration of PBLs and CD4(+) T cells, whereas neutralization of CXCL9 or inhibition of p38-C/EBP-ß pathway can significantly decrease the migration. Our data together demonstrate that HSV-2 induces CXCL9 expression in human cervical epithelial cells by activation of p38-C/EBP-ß pathway through promoting the binding of C/EBP-ß to CXCL9 promoter, which may recruit activated CD4(+) T cells to mucosal HSV-2 infection sites and potentially increase the risk of HIV-1 sexual transmission.
Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Chemokine CXCL9/biosynthesis , Epithelial Cells/virology , Herpes Simplex/metabolism , MAP Kinase Signaling System/immunology , Adult , Blotting, Western , CCAAT-Enhancer-Binding Protein-beta/immunology , CD4-Positive T-Lymphocytes/immunology , Cervix Uteri/virology , Chemokine CXCL9/genetics , Chemotaxis, Leukocyte/genetics , Chemotaxis, Leukocyte/immunology , Chromatin Immunoprecipitation , Electrophoretic Mobility Shift Assay , Enzyme-Linked Immunosorbent Assay , Epithelial Cells/immunology , Epithelial Cells/metabolism , Female , Gene Expression Regulation/genetics , Gene Expression Regulation/immunology , Herpes Simplex/immunology , Herpesvirus 2, Human/immunology , Humans , Middle Aged , Promoter Regions, Genetic/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transfection , Young AdultABSTRACT
Glycosylation plays important roles in gp120 structure and HIV-1 immune evasion. In the current study, we introduced deglycosylations into the 24 N-linked glycosylation sites of a R5 env MWS2 cloned from semen and systematically analyzed the impact on infectivity, antigenicity, immunogenicity and sensitivity to entry inhibitors. We found that mutants N156-T158A, N197-S199A, N262-S264A and N410-T412A conferred decreased infectivity and enhanced sensitivity to a series of antibodies and entry inhibitors. When mice were immunized with the DNA of wild-type or mutated gp160, gp140 or gp120; N156-T158A, N262-S264A and N410-T412A were more effective in inducing neutralizing activity against wild-type MWS2 as well as heterologous IIIB and CH811 Envs. In general, gp160 and gp140 induced higher neutralizing activity compared with gp120. Our study demonstrates for the first time that removal of individual glycan N156, N262 or N410 proximal to CD4-binding region impairs viral infectivity and results in enhanced capability to induce neutralizing activity.
Subject(s)
Antibodies, Neutralizing/immunology , CD4 Antigens/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/immunology , HIV Infections/virology , HIV-1/physiology , Polysaccharides/immunology , Amino Acid Motifs , Amino Acid Sequence , Animals , Conserved Sequence , Female , Glycosylation , HIV Envelope Protein gp120/chemistry , HIV Infections/immunology , HIV-1/chemistry , HIV-1/genetics , HIV-1/immunology , Humans , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Protein BindingABSTRACT
High-mannose N-linked glycans recognized by carbohydrate-binding agents (CBAs) are potential targets for topical microbicides. To better understand the mechanisms by which CBAs inhibit human immunodeficiency virus (HIV)-1 infection at the molecular level, we systematically analysed the contribution of site-specific glycans to the anti-HIV activity of CBAs by site-directed mutagenesis. Our results demonstrate that a single deglycosylation at N295 or N448 in a range of primary and T-cell-line-adapted HIV-1 isolates resulted in marked resistance to griffithsin (GRFT) but maintained the sensitivity to cyanovirin (CV-N), Galanthus nivalis agglutinin (GNA) and a range of neutralizing antibodies. Unlike CV-N and GNA, the interaction between GRFT and gp120 appeared to be dependent on the specific trimeric 'sugar tower' including N295 and N448. This was further strengthened by the results of GRFT-Env binding experiments. Our study identifies GRFT-specific gp120 glycans and may provide information for the design of novel CBA antiviral strategies.
Subject(s)
Algal Proteins/metabolism , Antiviral Agents/metabolism , HIV Envelope Protein gp120/metabolism , HIV-1/drug effects , Lectins/metabolism , Mannose/metabolism , Antibodies, Neutralizing/metabolism , Bacterial Proteins/metabolism , Carrier Proteins/metabolism , Glycosylation , HIV Antibodies/metabolism , HIV Envelope Protein gp120/genetics , HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Humans , Mannose-Binding Lectins/metabolism , Mutagenesis, Site-Directed , Plant Lectins/metabolism , Protein BindingABSTRACT
BACKGROUND: Geohelminth infections are highly prevalent infectious diseases of childhood in many regions of the Tropics, and are associated with significant morbidity especially among pre-school and school-age children. There is growing concern that geohelminth infections, particularly exposures occurring during early life in utero through maternal infections or during infancy, may affect vaccine immunogenicity in populations among whom these infections are endemic. Further, the low prevalence of allergic disease in the rural Tropics has been attributed to the immune modulatory effects of these infections and there is concern that widespread use of anthelmintic treatment in high-risk groups may be associated with an increase in the prevalence of allergic diseases. Because the most widely used vaccines are administered during the first year of life and the antecedents of allergic disease are considered to occur in early childhood, the present study has been designed to investigate the impact of early exposures to geohelminths on the development of protective immunity to vaccines, allergic sensitization, and allergic disease. METHODS/DESIGN: A cohort of 2,403 neonates followed up to 8 years of age. Primary exposures are infections with geohelminth parasites during the last trimester of pregnancy and the first 2 years of life. Primary study outcomes are the development of protective immunity to common childhood vaccines (i.e. rotavirus, Haemophilus influenzae type B, Hepatitis B, tetanus toxoid, and oral poliovirus type 3) during the first 5 years of life, the development of eczema by 3 years of age, the development of allergen skin test reactivity at 5 years of age, and the development of asthma at 5 and 8 years of age. Potential immunological mechanisms by which geohelminth infections may affect the study outcomes will be investigated also. DISCUSSION: The study will provide information on the potential effects of early exposures to geohelminths (during pregnancy and the first 2 years of life) on the development of vaccine immunity and allergy. The data will inform an ongoing debate of potential effects of geohelminths on child health and will contribute to policy decisions on new interventions designed to improve vaccine immunogenicity and protect against the development of allergic diseases. TRIAL REGISTRATION: Current Controlled Trials ISRCTN41239086.
Subject(s)
Asthma/immunology , Eczema/immunology , Helminthiasis/immunology , Hypersensitivity/immunology , Pregnancy Complications, Parasitic/immunology , Vaccines/immunology , Asthma/epidemiology , Child , Child, Preschool , Ecuador/epidemiology , Eczema/epidemiology , Epidemiologic Research Design , Female , Helminthiasis/epidemiology , Humans , Hypersensitivity/epidemiology , Immunity, Innate/immunology , Infant , Infant, Newborn , Longitudinal Studies , Models, Immunological , Pregnancy , Pregnancy Complications, Parasitic/epidemiology , Pregnancy Complications, Parasitic/parasitology , Skin TestsABSTRACT
In spite of having effective, safe treatment for tuberculosis, the prevalence, incidence and mortality remain high. One of the ways to improve control of the disease is to reduce treatment duration either with currently used drugs or with the development of new drugs. These will all require clinical testing for safety and efficacy. The increasing complexity of regulations governing the conduct of clinical trials poses a threat to the very indications for which they are intended. There is an urgent need to review and harmonise the guidelines so that they can be administered in a way that does not compromise the safety and well-being of the trial subjects.
Subject(s)
Antitubercular Agents/pharmacology , Clinical Trials as Topic , Practice Guidelines as Topic , Tuberculosis/drug therapy , Antitubercular Agents/administration & dosage , Antitubercular Agents/adverse effects , Drug Administration Schedule , Humans , Risk Factors , Tuberculosis/epidemiology , United Kingdom/epidemiologyABSTRACT
Geohelminth infections are associated with modulation of immunity to parasite antigens and aeroallergens. To investigate the possibility that this modulation is affected by anthelmintic treatment, we compared cytokine responses in children who were treated with repeated doses of albendazole over 1 year versus those in children who had were not treated. Whole-blood samples were cultured with Ascaris antigen and house dust mite and cockroach allergens, and levels of interleukin (IL)-5, IL-13, interferon-gamma, and IL-10 were measured. Anthelmintic treatment was associated with enhanced production of Th2 cytokines in response to parasite antigen but did not affect responses to aeroallergens. The data indicate that long-term treatment may be associated with increased Th2 antiparasite immunity.
Subject(s)
Albendazole , Allergens/immunology , Anthelmintics , Ascariasis/immunology , Ascaris lumbricoides/drug effects , Rural Population , Th2 Cells/immunology , Albendazole/administration & dosage , Albendazole/therapeutic use , Animals , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Ascariasis/drug therapy , Ascariasis/epidemiology , Ascariasis/parasitology , Ascaris lumbricoides/immunology , Child , Cockroaches/immunology , Cytokines/biosynthesis , Cytokines/immunology , Dust/immunology , Ecuador/epidemiology , Female , Humans , Hypersensitivity, Immediate/epidemiology , Hypersensitivity, Immediate/etiology , Hypersensitivity, Immediate/immunology , Male , Mites/immunology , Skin Tests , Treatment Outcome , Tropical ClimateABSTRACT
BACKGROUND: The environmental factors that determine the elevated levels of polyclonal IgE observed in populations living in the Tropics are poorly understood but may include geohelminth infections. We investigated the association between geohelminth infections and total IgE levels in school children in rural tropical Ecuador, and assessed the effect on IgE of repeated anthelmintic treatments over a period of 12 months. The study was nested within a cluster-randomized study that randomized 68 schools to receive either 400 mg of albendazole every 2 months over a year or no treatment. We studied random samples of children completing follow-up and representing four groups stratified by the presence of geohelminth infection at baseline and treatment allocation. We measured levels of total IgE and anti-A. lumbricoides IgG (used as a measure of past and current geohelminth infectious exposure) in blood samples collected at the start of the study and after 12 months. RESULTS: We observed elevated levels of total IgE (compared to standard reference values) at the start of the study in this population of school children (geometric mean, 1,004 IU/mL, range 12 to 22,608 IU/mL)) and baseline IgE levels were strongly associated with parameters of geohelminth infection but not with age, nutritional and socioeconomic status. After 12 months, levels of IgE fell significantly in the treatment (by 35.1%) and no treatment (by 10.4%) groups, respectively, but the fall was significantly greater in the treatment group. Falls in IgE were independently associated with albendazole treatment, having a baseline geohelminth infection and with high baseline levels of anti-A. lumbricoides IgG. Increases in IgE at 12 months were associated with the presence of geohelminth infections and increasing levels of anti-A. lumbricoides IgG at 12 months independent of treatment allocation. CONCLUSION: The data provide evidence that geohelminth infections are an important determinant of total IgE in school children in the rural Tropics and that periodic anthelmintic treatments over 12 months are associated with reductions in IgE. The failure of anthelmintic treatment to reduce IgE levels to that considered normal in industrialized countries may be attributed to continued exposure of children to geohelminths or to the effects of infections in early life in programming a long-lasting Th2-biassed immunity.
Subject(s)
Albendazole/therapeutic use , Anthelmintics/therapeutic use , Helminthiasis/drug therapy , Helminthiasis/immunology , Immunoglobulin E/blood , Albendazole/administration & dosage , Animals , Anthelmintics/administration & dosage , Antibodies, Helminth/blood , Ascaris lumbricoides/immunology , Child , Ecuador/epidemiology , Female , Helminthiasis/epidemiology , Helminths/immunology , Humans , Immunoglobulin G/blood , Male , Prevalence , Rural PopulationABSTRACT
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a multisystem disease, the pathogenesis of which remains undetermined. We set out to determine the precise abnormalities of gene expression in the blood of patients with CFS/ME. We analyzed gene expression in peripheral blood from 25 patients with CFS/ME diagnosed according to the Centers for Disease Control and Prevention diagnostic criteria and 50 healthy blood donors, using a microarray with a cutoff fold difference of expression of >or=2.5. Genes showing differential expression were further analyzed in 55 patients with CFS/ME and 75 healthy blood donors, using quantitative polymerase chain reaction. Differential expression was confirmed for 88 genes; 85 were upregulated, and 3 were downregulated. Highly represented functions were hematological disease and function, immunological disease and function, cancer, cell death, immune response, and infection. Clustering of quantitative polymerase chain reaction data from patients with CFS/ME revealed 7 subtypes with distinct differences in Medical Outcomes Survey Short Form-36 scores, clinical phenotypes, and severity.
Subject(s)
Fatigue Syndrome, Chronic/genetics , Adult , Cluster Analysis , Fatigue Syndrome, Chronic/blood , Female , Gene Expression Profiling , Gene Expression Regulation , Humans , Male , Multigene Family , Oligonucleotide Array Sequence Analysis/methods , Polymerase Chain Reaction , Promoter Regions, Genetic , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Transcription Factors/geneticsABSTRACT
Twenty-eight adults received between 10(2) and 10(8)colony forming units of live Shigella dysenteriae type-1 vaccine SC599, attenuated by deletion of invasion (icsA), iron chelation (ent, fep) and shiga toxin A-subunit (stxA) genes, followed by ciprofloxacin on day 4. Dose-independent diarrhea or change in bowel habit was seen in 3 subjects, without dysentery, vaccinaemia or serious adverse events. Hematology and biochemical parameters were unchanged. Doses of 10(5) or greater induced dose-independent SD1 lipopolysaccharide-specific antibody secreting cell (ASC) responses. Geometric mean number of IgA ASCs per 10(6) PBMCs for 10(5), 10(6), 10(7) and 10(8) groups were respectively 41, 8.8, 26 and 8.5. Serum antibody responses were seen in three subjects. SC599 appears immunogenic with maximum tolerated dose greater than 10(8)CFU.
Subject(s)
Dysentery, Bacillary/prevention & control , Gene Deletion , Shigella Vaccines/adverse effects , Shigella Vaccines/immunology , Shigella dysenteriae/immunology , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Administration, Oral , Adult , Antibodies, Bacterial/blood , Bacterial Proteins/genetics , DNA-Binding Proteins/genetics , Enterobactin/genetics , Female , Humans , Male , Protein Subunits/genetics , Shiga Toxin/genetics , Shigella Vaccines/administration & dosage , Shigella dysenteriae/genetics , Transcription Factors/genetics , Treatment Outcome , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/agonistsABSTRACT
Macrophages and dendritic cells are involved in the immune response to Mycobacterium tuberculosis (Mtb). Such a response, although extensively studied using animal models and cells from human blood, has not been characterized in cells from pulmonary hilar lymph nodes (PHLN). We characterized populations of myeloid APC from PHLN and determined their expression of CCR2, CCR5, CCR7, CD40, CD54, CD80, and CD86 as well as the cytokine/chemokine microenvironment before and after purified protein derivative (PPD) and mannosilated lipoarabinomannan (ManLAM) stimulation. Results show that there are at least three APC populations in PHLN, defined as CD14highHLA-DRlow/-, CD14dimHLA-DRdim, and CD14-HLA-DRhigh/dendritic cells (DC), with the largest number represented by CD14dimHLA-DRdim cells (where dim indicates intermediate levels). CD14-HLA-DRhigh/DC expressed higher levels of costimulatory molecules and lower levels of CCR2 and CCR5, but all cell populations showed similar CCR7 levels. PPD and ManLAM specifically down-regulated CCR2 expression but not that of CCR5 and CCR7, and such down-regulation was observed on all APC populations. Mtb Ag did not affect the expression of costimulatory molecules. PPD but not ManLAM specifically induced MCP-1/CCL2 production, which was likely associated with the induction of IFN-gamma because this cytokine was highly induced by PPD. We characterized, for the first time, different APC from human PHLN and show that Mtb Ag exert fine and specific regulation of molecules closely associated with the immune response to Mtb infection. Because knowledge of this response in secondary lymphoid tissues is still poorly understood in humans, such studies are necessary and important for a better understanding of lymphoid cell microenvironment and migrating capacities and their role in the immunopathogenesis of tuberculosis.
Subject(s)
Antigen-Presenting Cells/immunology , Antigens, Bacterial/immunology , Chemokine CCL2/metabolism , Lung/immunology , Lymphocytes/immunology , Receptors, CCR2/metabolism , Adult , Antigen Presentation , Antigen-Presenting Cells/drug effects , Antigens, Bacterial/pharmacology , Chemokine CCL2/analysis , Chemokines/metabolism , Child , Dendritic Cells/drug effects , Dendritic Cells/immunology , Flow Cytometry , Humans , Lipopolysaccharides/immunology , Lipopolysaccharides/pharmacology , Lymph Nodes/immunology , Lymphocytes/drug effects , Macrophages/immunology , Male , Monocytes/immunology , Receptors, CCR2/analysis , Receptors, Chemokine/metabolism , Tuberculin/immunology , Tuberculin/pharmacologyABSTRACT
Human T-lymphotropic virus type 1 (HTLV-1) is a persistent CD4+ T-lymphotropic retrovirus. Most HTLV-1-infected individuals remain asymptomatic, but a proportion develop adult T cell leukemia or inflammatory disease. It is not fully understood how HTLV-1 persists despite a strong immune response or what determines the risk of HTLV-1-associated diseases. Until recently, it has been difficult to quantify lymphocyte kinetics in humans in vivo. Here, we used deuterated glucose labeling to quantify in vivo lymphocyte dynamics in HTLV-1-infected individuals. We then used these results to address four questions. (i) What is the impact of HTLV-1 infection on lymphocyte dynamics? (ii) How does HTLV-1 persist? (iii) What is the extent of HTLV-1 expression in vivo? (iv) What features of lymphocyte kinetics are associated with HTLV-1-associated myelopathy/tropical spastic paraparesis? We found that CD4+CD45RO+ and CD8+CD45RO+ T lymphocyte proliferation was elevated in HTLV-1-infected subjects compared with controls, with an extra 10(12) lymphocytes produced per year in an HTLV-1-infected subject. The in vivo proliferation rate of CD4+CD45RO+ cells also correlated with ex vivo viral expression. Finally, the inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis was associated with significantly increased CD4+CD45RO+ cell proliferation. We suggest that there is persistent viral gene expression in vivo, which is necessary for the maintenance of the proviral load and determines HTLV-1-associated myelopathy/tropical spastic paraparesis risk.
Subject(s)
HTLV-I Infections/immunology , T-Lymphocytes/immunology , Cell Division , Gene Products, tax/analysis , Humans , Leukocyte Common Antigens/analysis , Lymphocyte Activation , Paraparesis, Tropical Spastic/immunology , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , T-Lymphocytes, Cytotoxic/immunologyABSTRACT
The majority of knowledge about the role of cytokines and chemokines in controlling Mycobacterium tuberculosis infection mainly derives from animal models. In humans, this knowledge is still mainly limited to the blood compartment or accessible lymphoid organs, such as tonsils. Here, we studied cytokine and chemokine production and their modulation by M. tuberculosis antigens in mononuclear cells from human blood, spleen and hilar lung lymph nodes. Results show that the kinetics and magnitude of cytokine and chemokine production varied according to the tissue of cell origin. Mycobacterium tuberculosis antigens enhanced cytokine and chemokine production in blood, but the enhancement was restricted in spleen and hilar lung lymph node cells. We show, for the first time in humans, differences in cytokine and chemokine microenvironments according to lymphoid tissues, and suggest that these differences may affect the way cells respond to M. tuberculosis infection.
Subject(s)
Antigens, Bacterial/immunology , Chemokines/biosynthesis , Cytokines/biosynthesis , Leukocytes, Mononuclear/immunology , Lymphoid Tissue/immunology , Mycobacterium tuberculosis/immunology , Adolescent , Adult , Blood/immunology , Cells, Cultured , Child , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle AgedABSTRACT
Human natural killer (NK) cells form a circulating population in a state of dynamic homeostasis. We investigated NK cell homeostasis by labelling dividing cells in vivo using deuterium-enriched glucose in young and elderly healthy subjects and patients with viral infection. Following a 24-hr intravenous infusion of 6,6-D(2)-glucose, CD3(-) CD16(+) NK cells sorted from peripheral blood mononuclear cells (PBMC) by fluorescence-activated cell sorter (FACS) were analysed for DNA deuterium content by gas chromatography mass spectrometry to yield minimum estimates for proliferation rate (p). In healthy young adults (n=5), deuterium enrichment was maximal approximately 10 days after labelling, consistent with postmitotic maturation preceding circulation. The mean (+/- standard deviation) proliferation rate was 4 x 3 +/- 2 x 4%/day (equivalent to a doubling time of 16 days) and the total production rate was 15 +/- (7 x 6) x 10(6) cells/l/day. Labelled cells disappeared from the circulation at a similar rate [6 x 9 +/- 4 x 0%/day; half-life (T((1/2))) < 10 days]. Healthy elderly subjects (n=8) had lower proliferation and production rates (P=2 x 5 +/- 1 x 0%/day and 7 x 3 +/- (3 x 7) x 10(6) cells/l/day, respectively; P=0 x 04). Similar rates were seen in patients chronically infected with human T-cell lymphotropic virus type I (HTLV-I) (P=3 x 2 +/- 1 x 9%/day). In acute infectious mononucleosis (n=5), NK cell numbers were increased but kinetics were unaffected (P=2 x 8 +/- 1 x 0%/day) a mean of 12 days after symptom onset. Human NK cells have a turnover time in blood of about 2 weeks. Proliferation rates appear to fall with ageing, remain unperturbed by chronic HTLV-I infection and normalize rapidly following acute Epstein-Barr virus infection.